Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement
S Petersenn, M Fleseriu, FF Casanueva… - Nature Reviews …, 2023 - nature.com
Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …
sponsored by the Pituitary Society offers evidence-based graded consensus …
Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment
P Burman, O Casar-Borota… - The Journal of …, 2023 - academic.oup.com
Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …
regard to clinical presentation, proliferative markers, clinical course, and response to …
Therapeutic targeting of the pituitary tumor microenvironment
MD Ilie, D De Alcubierre, AL Carretti… - Pharmacology & …, 2023 - Elsevier
The tumor microenvironment (TME), the complex environment in which tumors develop, has
been increasingly targeted for cancer treatment in recent years. Aggressive pituitary tumors …
been increasingly targeted for cancer treatment in recent years. Aggressive pituitary tumors …
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors
After temozolomide failure, no evidence-based treatment option is currently available for
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …
Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset
M Luo, R Tang, H Wang - Journal of Neuro-Oncology, 2023 - Springer
Purpose Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs) and
application of current immunotherapy for refractory PitNETs remains debated. We aim to …
application of current immunotherapy for refractory PitNETs remains debated. We aim to …
Tumour microenvironment and pituitary tumour behaviour
P Marques, M Korbonits - Journal of Endocrinological Investigation, 2023 - Springer
The pituitary tumour microenvironment encompasses a spectrum of non-tumoural cells, such
as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like …
as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like …
PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas
G Cossu, S La Rosa, JP Brouland, N Pitteloud, E Harel… - Cancers, 2023 - mdpi.com
Simple Summary The biological behavior of Pituitary Neuroendocrine Tumors (PitNET)
remains unclear. Many efforts have been performed in order to clarify this point. The …
remains unclear. Many efforts have been performed in order to clarify this point. The …
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review
Purpose The purpose of this work was toinvestigate the clinicopathological characteristics at
the initial diagnosis of the pituitary tumor and at pituitary carcinoma (PC) diagnosis …
the initial diagnosis of the pituitary tumor and at pituitary carcinoma (PC) diagnosis …
Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment
I Shimon - Archives of Medical Research, 2023 - Elsevier
Prolactinomas are the most common functional pituitary tumors, accounting for 40% of all
pituitary adenomas. Medical treatment with dopamine agonists (DA), mainly cabergoline, is …
pituitary adenomas. Medical treatment with dopamine agonists (DA), mainly cabergoline, is …
Refractory lactotroph adenomas
SA Urwyler, N Karavitaki - Pituitary, 2023 - Springer
A small subset of lactotroph adenomas is resistant to dopamine agonists (DA) and can also
demonstrate aggressive or even malignant behavior. The implicated mechanisms are not …
demonstrate aggressive or even malignant behavior. The implicated mechanisms are not …